Why the study?
Does prophylactic ICD therapy reduce overall mortality in high-risk patients 6-40 days after an acute myocardial infarction?
Does prophylactic ICD therapy reduce overall mortality in high-risk patients 6-40 days after an acute myocardial infarction?
Prophylactic ICD implantation early (6-40 days) after acute myocardial infarction does not improve overall survival, as a reduction in arrhythmic deaths is offset by an increase in nonarrhythmic deaths.
Answers are grounded in this paper and cite their sources.
Does not support early prophylactic ICD after MI; leaves open optimal device timing pending further randomized data.
Background. Implantable cardioverter-defibrillator (ICD) therapy has been shown to improve survival in patients with various heart conditions who are at high risk for ventricular arrhythmias. Whether benefit occurs in patients early after myocardial infarction is unknown. Methods. We conducted the Defibrillator in Acute Myocardial Infarction Trial (DINAMIT), a randomized, open-label comparison of ICD therapy (in 332 patients) and no ICD therapy (in 342 patients) 6–40 days after myocardial infarction. We enrolled patients who had reduced left ventricular function (left ventricular ejection fraction, 0.35 or less) and impaired cardiac autonomic function (manifested as depressed heart-rate variability or an elevated average 24-hour heart rate on Holter monitoring). The primary outcome was mortality from any cause. Death from arrhythmia was a predefined secondary outcome. Results. During a mean (± SD) follow-up period of 30±13 months, there was no difference in overall mortality between the two treatment groups: of the 120 patients who died, 62 were in the ICD group and 58 in the control group (hazard ratio for death in the ICD group, 1.08; 95% confidence interval [CI], 0.76–1.55; p=0.66). There were 12 deaths due to arrhythmia in the ICD group, as compared with 29 in the control group (hazard ratio in the ICD group, 0.42; 95% CI, 0.22–0.83; p=0.009). In contrast, there were 50 deaths from non-arrhythmic causes in the ICD group and 29 in the control group (hazard ratio in the ICD group, 1.75; 95% CI, 1.11–2.76; p=0.02). Conclusions. Prophylactic ICD therapy does not reduce overall mortality in high-risk patients who have recently had a myocardial infarction. Although ICD therapy was associated with a reduction in the rate of death due to arrhythmia, that was offset by an increase in the rate of death from nonarrhythmic causes.—Hohnbser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;35l:248l–2488. Comment. We review the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) below, so it is timely to review another important trial: the DINAMIT—the first randomized controlled study to assess the impact of implantable cardioverter-defibrillator (ICD therapy very early after myocardial infarction (MI). DINAMIT was designed to test whether prophylactic implantation of an ICD would reduce mortality in survivors of a recent MI who are at high risk for ventricular arrhythmias. Patients aged 18–80 years were enrolled if they recently had an MI (6–40 days previously) and if they had a left ventricular ejection fraction of 35% or less. This trial randomized 674 patients within 40 days of an acute MI to current standard medical therapy with or without an ICD and followed them for a mean of 2.5 years. Three hundred thirty-two patients were randomly assigned to the ICD group and 342 to the control group. The mean left ventricular ejection fraction was 28%. The average time from MI to randomization was 18 days and was similar in the two groups. There was excellent adherence to optimal medical therapy in both groups, which included angiotensin-converting enzyme inhibitors, β blockers, aspirin, and lipid-lowering drugs. Patients who were randomly assigned to receive an ICD were required to undergo implantation of a market-approved, single-chamber ICD (St. Jude Medical, Sunnyvale, CA) within 1 week after randomization. The primary outcome in DINAMIT was death from any cause. Death due to cardiac arrhythmia was the secondary outcome. There was no difference in overall mortality between the two groups. Of the 120 who died, 62 were in the ICD group and 58 in the control group (hazard ratio for death in the ICD group, 1.08; p=0.66). There were 12 deaths due to arrhythmia in the ICD group compared with 29 among controls (hazard ratio for the ICD group, 0.42; p=0.009). In contrast, there were 50 deaths from nonarrhythmic causes in the ICD group, but only 29 in the controls (hazard ratio for the ICD group, 1.75; p=0.02). In essence, in DINAMIT, the reduction in the rate of arrhythmia-related death was very similar to that observed in previous trials of ICD therapy. In contrast to the previous trials, however, DINAMIT revealed a statistically significant increase in the rate of death from nonarrhythmic causes among patients assigned to receive an ICD. Most of these deaths (78%) were cardiovascular in nature. It appears that in DINAMIT, as in previous trials of ICD therapy, the ICD prevented death from ventricular fibrillation; however, preventing death from ventricular fibrillation did not reduce overall mortality in these patients. The reason for the unexpected and unprecedented increase in mortality from causes other than arrhythmia in patients assigned to receive an ICD is not clear. There was no sign of an increased rate of death in association with the surgical procedure or complications with the use of the ICD. It is unlikely that the increased rate of deaths from cardiac, nonarrhythmic causes was due to excessive pacing because the backup pacing was programmed at a very low rate in almost all the patients in the ICD group. Regardless of the plausible mechanism, this important clinical trial identifies a group of patients with risk factors for sudden death from cardiac causes in whom ICD therapy may not provide a survival benefit. DINAMIT suggests that patients with a recent MI and acute-onset left ventricular systolic dysfunction (left ventricular ejection fraction even less than 35%) do not benefit from ICDs for overall survival. One should wait until everything is stabilized following an MI—a period of perhaps 6 weeks—before prophylactic implantation of an ICD is considered.
No takes yet. Share an insight, caveat, or question.
Virk et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: